Evidence map›Paper›PMID 42039739›Full record

ReviewACS central science2026

Asymmetric Catalysis: Recent Advances toward a More Sustainable Synthesis.

Tanguy Saget, Mohamed Mellah, Philippe Dauban, Emmanuelle Schulz

Abstract readReview
In one paragraph

Review in ACS central science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tanguy SagetUniversité Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France.
Mohamed MellahInstitut de Chimie Moléculaire et des Matériaux d'Orsay, UMR 8182, Université Paris-Saclay, CNRS, Bâtiment Henri Moissan, 91400 Orsay, France.
Philippe DaubanUniversité Paris-Saclay, CNRS, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France.ORCID https://orcid.org/0000-0002-1048-5529
Emmanuelle SchulzInstitut de Chimie Moléculaire et des Matériaux d'Orsay, UMR 8182, Université Paris-Saclay, CNRS, Bâtiment Henri Moissan, 91400 Orsay, France.ORCID https://orcid.org/0000-0002-0844-8825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asymmetric catalysis is the most sustainable means of achieving efficient production of enantioenriched compounds, which are valuable to the pharmaceutical industry and advanced functionalized materials. The field has undergone considerable development since its inception about 60 years ago. The development of new chiral ligands or organocatalysts or the discovery of new reactions all led to spectacular progress in terms of activity and enantioselectivity. In this context, this Outlook article aims to highlight major advances that demonstrate the central role of asymmetric catalysis in sustainability, with the examples discussed representing a selection shaped by the authors' scientific perspective and sensitivity. This includes recent innovations in catalyst recycling, the use of less precious and less toxic metals in asymmetric organometallic catalysis, as well as the control of the positioning of catalytic sites, to further improve their efficiency. The development of asymmetric electrocatalysis and photocatalysis as well as of mechanochemistry and continuous flow chemistry is also discussed. Finally, the complexity and step-economy issues are raised with the presentation of relevant examples of asymmetric multicatalytic processes and new challenging transformations that include late-stage functionalization reactions, molecular edition or reactions targeting the creation of axial, planar or helicoidal chirality.

Identifiers

PMID42039739
PMCPMC13105215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.